Sarepta Is Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says

Sarepta Therapeutics Inc. shares have been assigned a rare $0 price target by HC Wainwright & Co. LLC, which maintained a sell rating, citing an "unwinnable" FDA dispute. This extreme downgrade follows Sarepta's refusal to voluntarily pause shipments of its lead therapy, Elevidys, despite an FDA request prompted by three deaths linked to the company's gene therapies, potentially leading to a market withdrawal of the treatment. The analyst firm views the regulatory conflict as critical, implying significant downside risk and a severe challenge to the company's core product.

Analysis

Sarepta Therapeutics Inc. (SRPT) is facing a critical valuation crisis following a rare and severe analyst action from HC Wainwright & Co. LLC, which reduced its price target on the stock to $0 from $10 while reaffirming a sell recommendation. The downgrade is predicated on what analyst Mitchell S. Kapoor describes as an 'unwinnable' confrontation with the US Food and Drug Administration (FDA). This dispute centers on Sarepta's refusal to voluntarily halt shipments of its lead gene therapy, Elevidys, despite an FDA request to do so. The regulatory concern is significant, stemming from three reported deaths linked to the company's gene therapies. The analysis implies that the potential for a forced market withdrawal of Elevidys represents an existential threat to the company, effectively wiping out its value.

Key Decisions for Investors

• Investors holding long positions in SRPT should consider the extreme downside risk highlighted by the $0 price target and the potential for a complete market withdrawal of its lead product.
• The situation presents a clear short-selling thesis based on the analyst's 'unwinnable' FDA fight scenario, with any formal regulatory action against Elevidys serving as a primary catalyst.
• All investors should closely monitor communications from both Sarepta and the FDA, as the company's viability is now almost entirely dependent on the outcome of this regulatory conflict.